Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$107.20
+0.3%
$108.63
$95.49
$148.06
$6.49B0.331.02 million shs167 shs
Envista Holdings Corporation stock logo
NVST
Envista
$19.67
+0.1%
$17.80
$14.22
$23.00
$3.34B0.992.49 million shs2.56 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€24.66
-1.7%
€23.02
€17.12
€25.88
€7.47B0.53339,247 shs544,500 shs
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$15.95
-0.3%
$15.39
$12.16
$27.95
$3.18B0.952.93 million shs3.05 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.00%-0.57%-1.27%-13.89%+0.16%
Envista Holdings Corporation stock logo
NVST
Envista
0.00%+4.29%+7.63%+13.73%+18.37%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.00%+5.47%+11.84%+21.06%+34.46%
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
0.00%+3.71%-0.56%+6.63%-36.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.8549 of 5 stars
4.51.00.04.02.23.32.5
Envista Holdings Corporation stock logo
NVST
Envista
3.4274 of 5 stars
2.23.00.03.81.50.01.9
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/AN/AN/AN/AN/A
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
4.8113 of 5 stars
3.15.04.23.83.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2.92
Moderate Buy$184.0071.64% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.33
Hold$20.232.84% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.86
Moderate BuyN/AN/A
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
2.15
Hold$20.3627.71% Upside

Current Analyst Ratings Breakdown

Latest XRAY, NVST, STVN, and JAZZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
6/3/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
5/27/2025
Envista Holdings Corporation stock logo
NVST
Envista
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/27/2025
Envista Holdings Corporation stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$21.00 ➝ $23.00
5/12/2025
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$20.00 ➝ $21.00
5/9/2025
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$27.00 ➝ $25.00
5/7/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$182.00 ➝ $172.00
5/7/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$167.00 ➝ $155.00
5/7/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$176.00 ➝ $147.00
5/7/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$183.00 ➝ $166.00
5/7/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.07B1.59$30.45 per share3.52$67.72 per share1.58
Envista Holdings Corporation stock logo
NVST
Envista
$2.51B1.33$1.66 per share11.84$17.05 per share1.15
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.19B6.25€0.76 per share32.64€5.02 per share4.91
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$3.79B0.84$7.38 per share2.16$9.77 per share1.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$560.12M$7.5014.295.734.6111.86%26.62%9.14%7/30/2025 (Estimated)
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B-$6.53N/A16.261.25-44.90%4.07%2.25%8/6/2025 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€127.45M€0.5148.3542.522.3511.14%10.00%6.03%N/A
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
-$910M-$4.54N/A8.391.14-24.42%14.31%5.37%7/30/2025 (Estimated)

Latest XRAY, NVST, STVN, and JAZZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$0.29$0.43+$0.14$0.10$854.75 million$879.00 million
5/6/2025Q1 2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million
5/1/2025Q1 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.20$0.24+$0.04$0.10$608.17 million$616.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$0.644.01%N/AN/A 13 Years

Latest XRAY, NVST, STVN, and JAZZ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.060.3%6/5/20256/5/20257/17/2025
5/21/2025
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
quarterly$0.163.92%6/27/20256/27/20257/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
1.28
3.38
2.97
Envista Holdings Corporation stock logo
NVST
Envista
0.43
2.12
1.82
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.83
1.26
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
0.79
1.10
0.76

Institutional Ownership

CompanyInstitutional Ownership
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
95.70%

Insider Ownership

CompanyInsider Ownership
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.30%
Envista Holdings Corporation stock logo
NVST
Envista
1.30%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
0.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,80060.51 million57.91 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,300169.49 million167.28 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
5,521302.84 millionN/AOptionable
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
14,000199.29 million198.26 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$107.20 +0.30 (+0.28%)
As of 09:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Envista stock logo

Envista NYSE:NVST

$19.67 +0.02 (+0.11%)
As of 09:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€24.66 -0.43 (-1.71%)
As of 06/27/2025 03:58 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

DENTSPLY SIRONA stock logo

DENTSPLY SIRONA NASDAQ:XRAY

$15.94 -0.06 (-0.34%)
As of 09:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform. It also provides endodontic products consisting of motorized endodontic handpieces, files, sealers, irrigation needles, and other tools that support root canal procedures; restorative products, including dental ceramics, crowns, and veneers; and preventative products, such as curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, and impression materials. In addition, the company offers SureSmile and Byte aligner solutions; VPro/HyperByte, a high-frequency vibration technology device; SureSmile Simulator, which creates a 3D visualization of a patient's outcome; and Byte Plus for treatment planning. Further, it provides dental implants, digital dentures, crown and bridge porcelain products, bone regenerative and restorative solutions, treatment planning software, and educational programs; dental prosthetics; urology catheters; and other health-related consumables. The company serves professional dental and consumable medical device markets through third-party distributors. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina